Today: 9 June 2026
Browse Category

NASDAQ:APLS 30 October 2025 - 21 May 2026

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, ending APLS trading on Nasdaq as of May 15. Former Apellis shareholders receive $41 per share in cash and a contingent value right tied to future Syfovre sales. Biogen shares rose 0.6% early Thursday. The CVR pays only if Syfovre meets specific sales milestones; there is no guarantee of payout.
21 May 2026
···
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Biogen completed its acquisition of Apellis Pharmaceuticals, removing APLS shares from Nasdaq and paying investors $41 per share plus a contingent value right tied to Syfovre sales. Apellis shareholders tendered 82.4% of outstanding stock before the offer expired May 13. Biogen shares rose 0.9% to $192.34 Wednesday. The CVR could pay up to $4 if Syfovre meets future sales targets.
20 May 2026
····
Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen completed its acquisition of Apellis Pharmaceuticals last week, delisting Apellis from Nasdaq after accepting 82.4% of shares in a $41-per-share cash deal plus a contingent value right. Apellis became a Biogen subsidiary on May 14. The CVR will pay holders up to $4 if Syfovre sales meet specified targets. Biogen shares closed at $192.95 on Friday.
17 May 2026
··
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
15 May 2026
···
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
14 May 2026
···
Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Biogen agreed to buy Apellis Pharmaceuticals for $5.6 billion, offering $41 per share in cash plus sales-based rights tied to the eye drug Syfovre. Apellis shares traded at $40.23 after the announcement. The deal includes a contingent value right worth up to $4 if Syfovre hits certain sales milestones. Apellis’ board and key shareholders, holding 14%, backed the offer, which is expected to close in the second quarter.
1 April 2026
···
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis Pharmaceuticals reported Q3 2025 revenue of $458.6 million and a $215.7 million net profit, but its stock fell about 21% after management warned of future losses. Syfovre sales in the U.S. were flat at $150.9 million, with modest injection growth and ongoing debate over its benefits. Empaveli gained FDA approval for rare kidney diseases in July. Analyst ratings and price targets remain divided.
30 October 2025
·

Stock Market Today

  • Calculate How a 22% Social Security Cut in 2032 Could Affect Your Retirement
    June 9, 2026, 12:45 PM EDT. The latest Social Security Trustees report projects a 22% reduction in benefits by 2032. This potential cut could significantly impact retirees relying on these payments. Understanding the exact effect on your retirement income is crucial for planning. Experts suggest evaluating your financial strategy now to adjust for possible decreased Social Security revenue. Early preparation can help mitigate risks tied to this forecasted decline in benefits.

Latest articles

BlackBerry Shares Stall After QNX Push

BlackBerry Shares Slip Ahead of Results — What’s Moving BB Today

9 June 2026
BlackBerry’s U.S. shares plunged 8.5% to $8.50 as investors braced for the June 25 earnings report, with focus on whether the company can meet its bullish Q1 revenue forecast of $132–$140 million, well above analysts’ estimates, after QNX’s 20% revenue jump and $950 million royalty backlog last quarter.
Chip Selloff Trips Up Wall Street’s AI Rally

Chip Selloff Trips Up Wall Street’s AI Rally

9 June 2026
Nasdaq and S&P 500 tumbled midday, erasing early chip-stock gains as tech shares slid; Philadelphia Semiconductor Index dropped 2% after jumping 3%, with Broadcom, Micron, and Nvidia under pressure. Investors await key inflation data Wednesday and SpaceX’s massive IPO, both seen as catalysts for further volatility amid concerns that high valuations in AI and tech could face profit-taking if rate fears persist.
Nintendo and Sanrio Stocks Get New AI Boost

Nintendo and Sanrio Stocks Get New AI Boost

9 June 2026
Nintendo hikes Switch 2 prices in Japan and the US, citing higher memory costs and tariffs expected to add 100 billion yen to annual expenses; investors now question whether Japan’s top entertainment brands like Nintendo and Sanrio can maintain valuations as AI-driven capital shifts toward chips and automation, pressuring stock selection even as the Nikkei rebounds 2.17% after Monday’s sharp drop.
Costco Drops Kirkland Prices While Prepping New Florida Warehouse

Costco Drops Kirkland Prices While Prepping New Florida Warehouse

9 June 2026
Costco slashed prices on select Kirkland Signature products by up to $10 as part of its strategy to boost membership renewals, but shares barely moved, last at $973.50, down $1.25, after Q3 net sales rose 11.6% to $69.15 billion and net income hit $2.19 billion; management emphasized the cuts are strategic, not a chainwide rollback, amid slowing paid membership growth and ongoing competitive pressure.
Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Go toTop